{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["sitravatinib","nivolumab"]],"indication":null,"name":"SAPPHIRE","nct_id":"NCT03906071","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sapphire-nct03906071. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SAPPHIRE","arms":[{"description":"Nivolumab will be administered by intravenous infusion over 30 minutes at 240 mg every 2 weeks or at 480 mg every 4 weeks. Sitravatinib capsules will be administered orally, once daily.","label":"Nivolumab and Sitravatinib","type":"EXPERIMENTAL"},{"description":"Docetaxel will be administered by intravenous infusion at 75 mg/m2 over 1 hour every 3 weeks.","label":"Docetaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2025-09-30","type":"ACTUAL"},"conditions":["Metastatic Non-Squamous Non-Small Cell Lung Cancer"],"enrollment":{"count":577,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","otherNames":["Opdivo"],"type":"BIOLOGICAL"},{"name":"Sitravatinib","otherNames":["MGCD516"],"type":"DRUG"},{"name":"Docetaxel","otherNames":["Taxotere"],"type":"DRUG"}],"last_update":"2026-09-30","lead_sponsor":"Mirati Therapeutics Inc.","official_title":"A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-03-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"From randomization date to date of death due to any cause (Up to approximately 44 months)"}],"references":[],"start_date":{"date":"2019-07-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03906071"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sapphire-nct03906071"}